Physician profile
Jamuna Rajasingham
NPI 1073756474
$25,868.80
in general payments reported to CMS, 2019-2025
66 companies · $4,525 in 2025
The $4,525 reported for 2025 was more than what 84% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,484 · 2020: $1,592 · 2021: $3,134 · 2022: $3,898 · 2023: $5,215 · 2024: $5,021 · 2025: $4,525.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $14K · Education: $265.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $14,495.30 |
| Education | $265.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $5,264.59 | 2019-2025 | Austedo Xr, Austedo, Austedo Xr |
| Abbvie INC. | $2,278.49 | 2019-2025 | |
| Emd Serono, INC. | $1,710.65 | 2019-2024 | Mavenclad |
| Acadia Pharmaceuticals INC | $1,583.94 | 2019-2025 | Nuplazid, Daybue |
| Neurocrine Biosciences, INC. | $1,462.06 | 2019-2025 | Ingrezza, Ongentys |
| Amgen INC. | $1,080.77 | 2019-2025 | Uplizna |
| Biogen, INC. | $1,028.50 | 2019-2025 | Tysabri, Vumerity, Qalsody |
| Novartis Pharmaceuticals Corporation | $852.74 | 2019-2025 | |
| Sk Life Science, INC. | $706.74 | 2021-2025 | Xcopri |
| Allergan, INC. | $617.69 | 2019-2022 | |
| Celgene Corporation | $575.92 | 2021-2025 | Zeposia |
| Lundbeck LLC | $557.90 | 2020-2025 | Vyepti, Rexulti |
| Eisai INC. | $540.67 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $537.34 | 2023-2025 | Rexulti, Nuedexta |
| Pfizer INC. | $515.30 | 2021-2025 |
Show all 66 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jamuna Rajasingham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.